# Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

> **NCT02110992** · PHASE1 · TERMINATED · sponsor: **University of Cincinnati** · enrollment: 7 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Docetaxel
- **RADIATION:** Stereotactic Radiation

## Key facts

- **NCT ID:** NCT02110992
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2017-03-29
- **Final completion:** 2017-03-29
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110992, "Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02110992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*